Biotech Values

[DewDiligence]

(REGN)—SNY ends diabetes/CV research—projects mega-blockbuster sales for Dupixent:

https://www.globenewswire.com/news-release/2019/12/09/1958232/0/en/Sanofi-CEO-unveils-new-strategy-to-drive-innovation-and-growth.html

https://www.wsj.com/articles/sanofi-to-buy-cancer-biotech-company-synthorx-for-2-5-billion-11575888370

Instead, Sanofi will focus its efforts on a range of specialty diseases—including hemophilia, breast cancer and multiple sclerosis—and vaccines. Mr. Hudson [CEO] highlighted Dupixent, an injected treatment for eczema and asthma that he said “has the chance to be one of the most successful medicines in the history of the industry.” Sanofi on Monday set a target to eventually hit €10 billion ($11 billion) in annual sales for Dupixent. The drug is on track to generate around €2 billion in 2019.

Sanofi also plans to separate its over-the-counter medicines business, which makes nonprescription treatments for common ailments such as colds and indigestion, into a stand-alone unit.

This announcement is a lead-in to tomorrow’s “Capital Markets Day” presentation (https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/capital-markets-day-2019 ).